Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Friday morning, Benzinga reports. HC Wainwright currently has a $50.00 price objective on the stock.

Several other equities research analysts have also recently weighed in on GMAB. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Royal Bank of Canada raised Genmab A/S from a sector perform rating to an outperform rating in a research report on Monday, July 15th. Truist Financial cut their target price on Genmab A/S from $53.00 to $50.00 and set a buy rating on the stock in a research note on Monday, September 9th. Morgan Stanley restated an equal weight rating and issued a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. Finally, BTIG Research boosted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus target price of $45.20.

Genmab A/S Trading Down 5.4 %

Shares of NASDAQ:GMAB opened at $24.14 on Friday. Genmab A/S has a 12 month low of $24.05 and a 12 month high of $36.71. The company has a 50-day moving average price of $27.22 and a 200 day moving average price of $27.94. The company has a market cap of $15.96 billion, a price-to-earnings ratio of 20.12, a PEG ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, equities analysts forecast that Genmab A/S will post 1.27 EPS for the current year.

Institutional Trading of Genmab A/S

Several institutional investors and hedge funds have recently bought and sold shares of GMAB. Russell Investments Group Ltd. lifted its stake in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after purchasing an additional 544 shares during the period. GAMMA Investing LLC grew its holdings in Genmab A/S by 194.0% in the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after purchasing an additional 749 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Genmab A/S during the 1st quarter worth approximately $43,000. Barometer Capital Management Inc. acquired a new stake in Genmab A/S in the 4th quarter valued at $121,000. Finally, Headlands Technologies LLC increased its holdings in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after acquiring an additional 4,853 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.